Cologne, Germany will host what the international life science industry considers to be its most productive annual partnering event, BIO-Europe®, taking place November 7-9, 2016. The conference brings together top decision makers from global life science companies in search of in-licensing and investment opportunities for deals that propel drug development.2016 AAPS Annual Meeting and Exposition
The 2016 AAPS Annual Meeting and Exposition will bring together more than 6,500 scientists, business leaders, government officials, and students from around the world to share and learn the latest scientific advances and industry developments. ...Generics giant Teva joins its adversaries’ lobby
W hy are the gates of the sheep pen wide open to invite the wolf in? The question may seem exaggerated, but it is raised by the admission of Teva Pharmaceutical Industries into the major American professional organisation of pharmaceutical companies, PhRMA (Pharmaceutical Research and Manufacturers of America) on 15 July...Biosimilars become reality
B iosimilars are becoming a reality in the pharmaceutical industry. This is a consequence of many Phase III biosimilar studies having now been completed or nearing conclusion. Biosimilar developers have become highly adept at demonstrating biosimilarity with originator products in the clinical setting and regulators – in the EU and various other non-US markets at least – have become seasoned approvers of biosimilar drugs. Even the FDA is now approaching the regulatory process with more confidence. If the European biosimilars market has now entered a “commercialisation phase”, the US market is not far behind. ...PHARMAnetwork’s quarterly pharmaceutical deals insights
The volume of deals in Q2 declined. Around 50 deals have been announced by the pharmaceutical industry out of a total of more than 90 within the health industry (pharma, medical devices, etc.). Recent events such as Brexit have affected the global markets and are likely to have had an impact on the volume of M&As. However, we have noted an increase in the volume of transactions worth more than one billion dollars. Major factors contributing to the success of M&A are acquisitions at clinical trial phase of new molecules with great potential, combined with the expiration of blockbuster patents (Gleevec, Crestor, Seroquel, Zetia…). The increase in value terms of M&A deals during Q2 is mainly thanks to 40 major transactions announced by Gilead, Abbvie, Pfizer, Jazz pharmaceutical, Mylan and Merck, the total value of which came to more than 55 billion dollars. ...CMOs: Customer services
The European serialization project has proved to be one of the main factors leading the main CMOs to embark upon new customer service strategies. The implementation of the European serialization project and more broadly of the regulatory directives for serialization at the international level require massive investments, the implementation of complex techniques and an extremely rigorous operational organization. The most dynamic CMOs have transformed a major regulatory constraint into a sales argument by developing a regulatory service offering adapted to each region of the world. Several CMOs, such as Aesica, Recipharm, etc., have made this a major part of their communications strategy. ...
PHARMAnetwork magazine audience is comprised of the top executives across the pharmaceutical value chain, from R&D, to production, to finance - we have the top decision makers in the industry.
More than 90% of our subscribers hold key positions in the industry.
Learn more about who reads PHARMAnetwork magazine and how your brand can connect with that audience mail to: email@example.com
1 Rue de Lille
Tel: 33 (0)1 42 97 97 97
Fax: 33 (0)1 42 97 97 12